BioSpace News Archive

The U.S. Food and Drug Administration (FDA) has several solid PDUFA dates in the middle of February. Here’s a look.

Early results from University of Oxford’s RECOVERY trial showed Roche’s immunosuppressant Actemra reduced deaths and the need for mechanical ventilation in severe COVID patients.

Barry P. Boden, MD, received the Orthopaedic Research and Education Foundation Clinical Research Award, which recognizes outstanding clinical research related to musculoskeletal disease or injury.

The 2021 Kappa Delta Young Investigator Award was presented to Lin Han, PhD, for research on the structure and function of cartilage extracellular matrix and its impact on tissue regeneration and disease evolution in osteoarthritis.

The 2021 Kappa Delta Elizabeth Winston Lanier Award was presented to Farshid Guilak, PhD and his co-authors, Bradley T. Estes, PhD, and Franklin T. Moutos, PhD, for their research and development of technology to grow bioartificial cartilage using a patient’s own donor cells and seeding them on a novel scaffold that can be molded to match the shape of a patient’s joint.

The American Academy of Orthopedic Surgeons announced that the 2021 Kappa Delta Elizabeth Winston Lanier Award has been granted to Cytex Therapeutics founders Drs. Farshid Guilak, Bradley Estes and Frank Moutos.

Cato T. Laurencin, MD, PhD, was named the 2021 Kappa Delta Ann Doner Vaughn Award recipient for his 30 years of scientific research in musculoskeletal regenerative engineering, the field which he founded and brought to the forefront of translational medicine.

Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, announced today it will report financial results for the fourth quarter and full year 2020 after market close on Monday, February 22, 2021.

Conformis, Inc. (Nasdaq: CFMS) today announced it has priced an underwritten public offering of 80,952,381 shares of its common stock at an offering price of $1.05 per share.

TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, will participate in the 2021 BIO CEO & Investor Digital Conference, being held virtually on February 16-18, 2021.